Recent data showed that in patients undergoing radical resection of non‐small cell lung cancer (NSCLC), the serum of patients treated with propofol had a lower concentration of tumour angiogenesis‐related factors, such as vascular endothelial growth factor (VEGF) and transforming growth factor beta, than that in the sevoflurane group.27 The gene discussed is VEGFA; the disease is neoplasm.